Gilead's hep C meds keep churning, but execs see need for deals as U.S. sales slow

Gilead Sciences ($GILD) and its hep C juggernaut kept rolling in Q4, churning out street-beating sales of $4.9 billion. But it took strong growth overseas to overcome an expected falloff for Sovaldi and Harvoni in the U.S. While Gilead execs say there's lots of growth left in the hep C market, they acknowledged Tuesday that the company needs to be looking for M&A opportunities in areas such as oncology. Report

Suggested Articles

Alexion Pharmaceuticals names its first chief diversity officer as the rare disease specialist looks to cultivate diversity and inclusion.

Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began rebuilding its oncology pipeline. Those efforts have finally paid off.

AbbVie is tapping tennis star and migraine sufferer Serena Williams is its spokesperson in the latest CGRP migraine med marketing campaign.